Episode Details

Pfizer is betting big on the next wave of obesity treatments, snapping up Metsera to build a pipeline of ultra-long-acting GLP-1 drugs aimed at monthly dosing—potentially disrupting the current daily pill and weekly injection landscape. With ten phase three trials planned for this year and a possible first approval by 2028, the pharma giant is positioning itself as a heavyweight in the booming market. For investors, Pfizer offers a safer, more diversified play compared to smaller biotechs—leveraging its scale and infrastructure while trading at a discount that reflects the long road ahead. This isn’t just a gamble—it’s a strategic move to capture future upside with less downside risk.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/bbe4e93b3b1e35c0